APAC Severe Asthma Biologics Market Industry Trends and Forecast to 2034: Segmented by (Target, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.87 BnPlaceholder estimate
Estimate 2025$3.19 Bn21.9% of the global market
Projected 2034$8.28 Bn 160%Adds $5.10 Bn over 9 forecast years
CAGR 2025–203411.2%Faster than 61% of 180 Pharmaceuticals markets here
Key players5
APAC is 21.94% of the global market.
Among regions, the largest is North America at $7.19 Bn.
Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC, Novartis AG (see all)
Active clinical trials
39 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Severe Asthma Biologics Market Analysis Executive Summary
Severe asthma biologics are injections that block immune signals driving severe asthma attacks.
Key segments of the severe Asthma Biologics market include target (IL-5, IL-4/IL-13 and IgE) and age (Children and Adults).
Asia Pacific Severe Asthma Biologics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Severe Asthma Biologics Market Dynamics
Market Growth Drivers
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.
Opportunity
Earlier screening, new drug classes and home-based care give the severe Asthma Biologics market room to grow.
Market Restraints
Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the severe Asthma Biologics market.
Competitive Landscape for Severe Asthma Biologics Market in APAC
The severe Asthma Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Severe Asthma Biologics Market in APAC
Severe Asthma Biologics in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 39 studies on Severe Asthma Biologics that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for severe Asthma Biologics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Target
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Sanofi
7.2 Regeneron Pharmaceuticals
7.3 AstraZeneca
7.4 GSK
7.5 Novartis
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The severe Asthma Biologics market can be segmented based on various criteria, including target, age and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Severe Asthma Biologics right now, from free public sources.
Clinical trials
39 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Severe Asthma Biologics market in Asia Pacific?
Placeholder estimate: about $3.19 Bn in 2025, rising to about $8.28 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Severe Asthma Biologics market in Asia Pacific growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Severe Asthma Biologics market report cover?
The report splits the market by target (IL-5, IL-4/IL-13, IgE, TSLP), age (Children, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Severe Asthma Biologics market?
Key players include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC and Novartis AG.
What is driving the Severe Asthma Biologics market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.
How many clinical trials on Severe Asthma Biologics are running in Asia Pacific?
39 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Severe Asthma Biologics?
PubMed lists 322 papers on Severe Asthma Biologics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
Italy
Brazil
France
UK
Saudi Arabia
India
Ecuador
Mexico
Spain
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya
Pfizer Inc.